专利检索 ap:("BRISTOL-MYERS SQUIBB COMPANY" OR "Universite De Montreal") AND inv:"Pancras C. Wong" 第 1 页

1.

发明授权
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation 有权

公开(公告)号：US10428077B2

公开(公告)日：2019-10-01

申请号：US16020043

申请日：2018-06-27

申请人： BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL

发明人： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller

IPC分类号： C07D487/04 , C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00

摘要： The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

2.

发明授权
Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation 有权

公开(公告)号：US09862730B2

公开(公告)日：2018-01-09

申请号：US14396807

申请日：2013-04-24

申请人： BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal

发明人： R. Michael Lawrence , Michael M. Miller , Dietmar Alfred Seiffert , Shoshana L. Posy , Pancras C. Wong , Jacques Banville , Edward H. Ruediger , Daniel H. Deon , Alain Martel , François Tremblay , Julia Guy , Jean-François Lavallée , Marc Gagnon

IPC分类号： C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377

CPC分类号： C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00

摘要： The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.

3.

发明授权
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation 有权

公开(公告)号：US10047103B2

公开(公告)日：2018-08-14

申请号：US15593534

申请日：2017-05-12

申请人： BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal

发明人： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller

IPC分类号： C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00

CPC分类号： C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00

摘要： The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

4.

发明授权
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation 有权

公开(公告)号：US09688695B2

公开(公告)日：2017-06-27

申请号：US14396771

申请日：2013-04-24

申请人： BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal

发明人： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller

IPC分类号： C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553

CPC分类号： C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00

摘要： The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

5.

发明申请
IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权
标题翻译：作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑唑二酮衍生物

公开(公告)号：US20150133446A1

公开(公告)日：2015-05-14

申请号：US14396807

申请日：2013-04-24

申请人： BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal

发明人： R. Michael Lawrence , Michael M. Miller , Dietmar Alfred Seiffert , Shoshana L. Posy , Pancras C. Wong , Jacques Banville , Edward H. Ruediger , Daniel H. Deon , Alain Martel , François Tremblay , Julia Guy , Jean-François Lavallée , Marc Gagnon

IPC分类号： C07D513/04 , A61K31/506 , A61K31/5377 , A61K31/4355 , A61K31/433 , A61K31/4439

CPC分类号： C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00

摘要： The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.

摘要翻译： 本发明提供式（I）的咪唑并噻二唑化合物，其中A，B，D，Rx，R1，R2，R3，X1，X2和s如本文所定义，或其立体异构体，互变异构体，药学上可接受的盐或溶剂化物形式，其中所有变量如本文所定义。这些化合物是血小板聚集的抑制剂，因此可以用作药物。

6.

发明申请
IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 审中-公开

公开(公告)号：US20180305376A1

公开(公告)日：2018-10-25

申请号：US16020043

申请日：2018-06-27

申请人： BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL

发明人： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller

IPC分类号： C07D513/04 , A61K31/5377 , A61K31/435 , C07D487/04 , A61K31/541 , A61K31/553 , A61K31/433 , A61K31/496 , A61K31/497 , A61K31/454 , A61K45/06 , A61K31/4439 , A61K31/5025 , C07B59/00 , A61K31/55 , A61K51/04 , A61K31/5386 , C07D519/00

CPC分类号： C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00

摘要： The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

7.

发明申请
IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权
标题翻译：作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑并噻唑和咪唑并吡啶衍生物

公开(公告)号：US20150094297A1

公开(公告)日：2015-04-02

申请号：US14396771

申请日：2013-04-24

申请人： BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal

发明人： Jacques Banville , Roger Rèmillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller

IPC分类号： C07D513/04 , A61K31/541 , A61K31/5377 , A61K31/5025 , C07D487/04 , A61K31/497 , A61K31/454 , A61K31/4439 , A61K31/433 , A61K31/553 , A61K31/496

CPC分类号： C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00

摘要： The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

摘要翻译： 本发明提供式I的噻唑化合物，其中W，Y，R0，R2，R4，R5，R6，R7，X1，X2，X3和X4如本文所定义，或立体异构体，互变异构体，药学上可接受的盐，或其溶剂合物形式，其中所有变量如本文所定义。这些化合物是血小板聚集的抑制剂，因此可以用作治疗或预防血栓栓塞障碍的药物。